Empagliflozin Reversal of Arterial StiffnEss in Aging

Part of paid clinical trials in Columbia, Missouri.

Sponsor
University of Missouri-Columbia
Study ID
NCT06506422
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Aging
  • Arterial Stiffness

Eligibility Criteria

Sex
ALL
Age
60 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Empagliflozin 10 MG — DRUG
    10mg Empagliflozin daily for 12 weeks
  • Placebo — DRUG
    10mg Placebo daily for 12 weeks

Study Details

Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.

Key Dates

Start date
Aug 18, 2024
Status verified
Feb 2026
Primary completion
Oct 31, 2028
Completion
Feb 28, 2029

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin
    10mg Empagliflozin daily for 12 weeks
  • Placebo Comparator: Placebo
    10mg Placebo daily for 12 weeks

Primary Outcome Measure

Carotid Femoral Pulse Wave Velocity (cfPWV) [ Time Frame: Baseline (day 0), Week 4, Week 8, Final (week 12) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of MissouriColumbiaMissouri65211
Andrea Atkins, BSN
[email protected]
573-884-1222

Find similar trials in Columbia, MO

By research site
University of Missouri· Columbia, MO

Related Studies